HIGHLIGHTS
- who: Rayer Cassandra from the (UNIVERSITY) have published the research: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohnu2019s disease: a multicentre retrospective study, in the Journal: (JOURNAL)
- what: The abrogation of mucosal inflammation should be the main objective of treatments, prompting international guidelines to recommend mucosal healing as the main target for treatment strategies, and physician decision-making . The aim of this study was therefore to compare the efficacy of ustekinumab, vedolizumab, and a second anti-TNF agent in patients . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.